108 related articles for article (PubMed ID: 18972190)
1. Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies.
Coburger C; Lage H; Molnár J; Hilgeroth A
Pharm Res; 2009 Jan; 26(1):182-8. PubMed ID: 18972190
[TBL] [Abstract][Full Text] [Related]
2. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
3. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
5. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
6. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Aouali N; El Btaouri H; Dumontet C; Eddabra L; Malagarie-Cazenave S; Madoulet C; Morjani H
Oncol Rep; 2011 Apr; 25(4):1161-7. PubMed ID: 21318225
[TBL] [Abstract][Full Text] [Related]
8. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
Qi X; Chang Z; Song J; Gao G; Shen Z
Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
[TBL] [Abstract][Full Text] [Related]
10. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin.
Gao A; Wang X; Xiang W; Liang H; Gao J; Yan Y
J Pharm Pharmacol; 2010 Mar; 62(3):393-9. PubMed ID: 20487225
[TBL] [Abstract][Full Text] [Related]
12. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells.
Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J
Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765
[TBL] [Abstract][Full Text] [Related]
14. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
15. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
16. Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.
Baumert C; Günthel M; Krawczyk S; Hemmer M; Wersig T; Langner A; Molnár J; Lage H; Hilgeroth A
Bioorg Med Chem; 2013 Jan; 21(1):166-77. PubMed ID: 23199479
[TBL] [Abstract][Full Text] [Related]
17. Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells.
Ferrándiz-Huertas C; Fernández-Carvajal A; Ferrer-Montiel A
Int J Cancer; 2011 Jan; 128(1):192-205. PubMed ID: 20209493
[TBL] [Abstract][Full Text] [Related]
18. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
Yan F; Wang XM; Liu ZC; Pan C; Yuan SB; Ma QM
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):287-95. PubMed ID: 20525557
[TBL] [Abstract][Full Text] [Related]
19. Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein.
Pan Q; Lu Q; Zhang K; Hu X
Cancer Chemother Pharmacol; 2006 Jul; 58(1):99-106. PubMed ID: 16231181
[TBL] [Abstract][Full Text] [Related]
20. Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1.
Sun M; Xu X; Lu Q; Pan Q; Hu X
Cancer Lett; 2007 Feb; 246(1-2):300-7. PubMed ID: 16621244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
